BioNTech CEO Says New Covid Vaccines Will Be Needed in 2022

The head of Germany’s BioNTech SE, which developed the first Covid-19 vaccine along with Pfizer Inc., said a new formula will probably be needed by mid-2022 to protect against future virus mutations.

The head of BioNTech SE, the German company that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus.

Ugur Sahin, co-founder and chief executive officer of BioNtech, told the Financial Times that while current variants of Covid-19, such as the contagious delta strain, were not different enough to undermine current vaccinations, new strains will emerge that can evade booster shots and the body’s immune defenses.

“This year [a different vaccine] is completely unneeded, but by mid-next year, it could be a different situation,” he said. “This is a continuous evolution, and that evolution has just started.”

BioNTech partnered with U.S. pharmaceuticals giant Pfizer Inc. to develop its Covid-19 vaccine. Last month, the companies submitted initial data to U.S. regulators about the use of the vaccine in children aged 5 to 11, one step closer to bringing shots to school-age kids.

MOCTEN

 

In January 1993, EUNET launched the first online news website, MOCTEN.com (stands for Music Opinions Culture Technology Economy News), led by Eric Bach, Teus Hagen, Peter Collinson, Julf Helsingius, Daniel Karrenberg,...  Read more

×